Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock
Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock

Chinese cancer drugs developer InnoCare raises US$289 million after Hong Kong IPO is nearly 300 times oversubscribed

  • Retail investors subscribed to 7.48 billion shares, 298.75 times the shares offered to them, InnoCare said in a filing to Hong Kong exchange
  • Co-founder and CEO Jasmine Cui Jisong said ‘very supportive cornerstone investors’ agreed to buy US$164 million worth of shares

Topic |   IPO
Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock
Illustration of a cancer cell made in 3D software. China’s InnoCare Pharma has nine novel drug candidates, including lead prospect orelabrutinib that is undergoing phase two trials for three types of blood cancers. Photo: Shutterstock
READ FULL ARTICLE